floxacillin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, 6-aminopenicillanic acid derivatives 1183 5250-39-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • floxacillin
  • fluocloxacilin
  • flucloxacillin
  • fluoxacillin
  • flucloxacillin sodium
Antibiotic analog of CLOXACILLIN.
  • Molecular weight: 453.87
  • Formula: C19H17ClFN3O5S
  • CLOGP: 2.70
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 112.74
  • ALOGS: -3.92
  • ROTB: 3

Drug dosage:

DoseUnitRoute
2 g O
2 g P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 146.96 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.19 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.40 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.05 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1962 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metabolic acidosis 336.18 25.69 136 6074 44933 63437879
Drug interaction 149.37 25.69 145 6065 228986 63253826
Cellulitis 114.80 25.69 81 6129 81877 63400935
Pyroglutamic acidosis 113.13 25.69 23 6187 612 63482200
Pyroglutamate increased 90.68 25.69 18 6192 423 63482389
Swelling face 56.52 25.69 48 6162 63427 63419385
Neutropenic sepsis 53.67 25.69 28 6182 16410 63466402
Jaundice 50.63 25.69 33 6177 29218 63453594
Hiccups 48.69 25.69 15 6195 2216 63480596
Dermatitis allergic 44.36 25.69 24 6186 15124 63467688
Vascular device infection 44.06 25.69 19 6191 7293 63475519
Rash erythematous 39.58 25.69 33 6177 42477 63440335
Perforation 39.23 25.69 11 6199 1172 63481640
Swollen tongue 38.75 25.69 30 6180 34770 63448042
Ejection fraction decreased 38.17 25.69 25 6185 22307 63460505
Eczema herpeticum 35.36 25.69 7 6203 162 63482650
Hypokalaemia 35.28 25.69 47 6163 103757 63379055
Lip swelling 35.07 25.69 27 6183 31036 63451776
Poor peripheral circulation 33.77 25.69 13 6197 3736 63479076
Acute kidney injury 32.18 25.69 76 6134 263339 63219473
Sepsis 31.65 25.69 55 6155 153068 63329744
Anterior interosseous syndrome 30.16 25.69 4 6206 4 63482808
Rash 29.13 25.69 120 6090 560751 62922061
Neuropathy peripheral 29.13 25.69 45 6165 113622 63369190
Vulvovaginal inflammation 28.73 25.69 8 6202 831 63481981
Polyhydramnios 28.30 25.69 10 6200 2261 63480551
Clostridium difficile infection 27.38 25.69 23 6187 29899 63452913
Angiodermatitis 27.25 25.69 5 6205 76 63482736
Acute haemorrhagic oedema of infancy 26.50 25.69 4 6206 16 63482796

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 153.02 21.58 167 4433 225779 34726552
Metabolic acidosis 147.71 21.58 84 4516 43596 34908735
Pyroglutamic acidosis 127.63 21.58 25 4575 401 34951930
Pyroglutamate increased 80.41 21.58 16 4584 279 34952052
Drug reaction with eosinophilia and systemic symptoms 69.47 21.58 47 4553 32965 34919366
Drug level decreased 62.23 21.58 27 4573 7819 34944512
Immunosuppressant drug level decreased 61.99 21.58 17 4583 1237 34951094
Stevens-Johnson syndrome 57.95 21.58 34 4566 18605 34933726
Kounis syndrome 38.76 21.58 14 4586 2504 34949827
Acute kidney injury 38.55 21.58 107 4493 304881 34647450
Genitalia external ambiguous 36.62 21.58 8 4592 223 34952108
Congenital bladder anomaly 35.00 21.58 8 4592 275 34952056
Foetal hypokinesia 32.57 21.58 8 4592 376 34951955
Neonatal respiratory depression 31.77 21.58 8 4592 417 34951914
Heart transplant rejection 31.40 21.58 10 4590 1221 34951110
Osteomyelitis salmonella 30.10 21.58 5 4595 29 34952302
Penile exfoliation 29.51 21.58 6 4594 117 34952214
Inhibitory drug interaction 28.30 21.58 10 4590 1678 34950653
Liver injury 26.17 21.58 19 4581 14859 34937472
Drug level below therapeutic 25.03 21.58 13 4587 5602 34946729
Blister 24.82 21.58 22 4578 22836 34929495
Cellulitis 23.82 21.58 32 4568 52919 34899412
Gastric ulcer 23.11 21.58 18 4582 15632 34936699
Lip swelling 22.68 21.58 18 4582 16062 34936269

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metabolic acidosis 425.86 19.67 212 10538 82317 79651321
Drug interaction 283.14 19.67 312 10438 414871 79318767
Pyroglutamic acidosis 224.95 19.67 47 10703 1029 79732609
Pyroglutamate increased 166.35 19.67 34 10716 665 79732973
Cellulitis 104.84 19.67 99 10651 108961 79624677
Drug level decreased 104.81 19.67 47 10703 14355 79719283
Drug reaction with eosinophilia and systemic symptoms 61.07 19.67 58 10692 64186 79669452
Immunosuppressant drug level decreased 57.87 19.67 18 10732 1986 79731652
Acute kidney injury 56.77 19.67 176 10574 519228 79214410
Lip swelling 55.05 19.67 45 10705 40866 79692772
Swelling face 52.46 19.67 56 10694 71156 79662482
Stevens-Johnson syndrome 50.44 19.67 42 10708 39124 79694514
Jaundice 50.39 19.67 48 10702 53301 79680337
Dermatitis allergic 50.23 19.67 31 10719 18099 79715539
Drug level below therapeutic 49.93 19.67 25 10725 9745 79723893
Neutropenic sepsis 47.83 19.67 35 10715 27029 79706609
Swollen tongue 47.40 19.67 42 10708 42528 79691110
Clostridium difficile infection 47.30 19.67 42 10708 42643 79690995
Rash erythematous 40.04 19.67 44 10706 57725 79675913
Rash 39.32 19.67 168 10582 578190 79155448
Mouth swelling 38.52 19.67 18 10732 6033 79727605
Vascular device infection 34.80 19.67 20 10730 10256 79723382
Perforation 33.71 19.67 11 10739 1415 79732223
Kounis syndrome 31.23 19.67 14 10736 4268 79729370
Poor peripheral circulation 29.95 19.67 13 10737 3670 79729968
Penile exfoliation 29.72 19.67 6 10744 110 79733528
Heart transplant rejection 29.15 19.67 10 10740 1500 79732138
Eczema herpeticum 28.94 19.67 7 10743 301 79733337
Osteomyelitis salmonella 28.26 19.67 5 10745 43 79733595
Polyhydramnios 27.88 19.67 10 10740 1710 79731928
Chromaturia 27.86 19.67 25 10725 25721 79707917
Hypokalaemia 27.19 19.67 60 10690 143980 79589658
Angiodermatitis 25.77 19.67 5 10745 74 79733564
Lower respiratory tract infection 25.72 19.67 55 10695 129165 79604473
Liver function test abnormal 25.33 19.67 37 10713 64438 79669200
Blister 25.11 19.67 52 10698 119424 79614214
Ejection fraction decreased 25.11 19.67 27 10723 34550 79699088
Acidosis 25.04 19.67 21 10729 19741 79713897
Angioedema 24.76 19.67 40 10710 75995 79657643
Congenital bowing of long bones 24.48 19.67 4 10746 20 79733618
Vaginal discharge 23.88 19.67 14 10736 7449 79726189
Anterior interosseous syndrome 23.87 19.67 4 10746 24 79733614
Strawberry tongue 23.87 19.67 4 10746 24 79733614
Skin exfoliation 23.67 19.67 33 10717 55067 79678571
Anaphylactic reaction 23.21 19.67 41 10709 83702 79649936
Completed suicide 22.97 19.67 3 10747 245764 79487874
Malaise 22.93 19.67 128 10622 489741 79243897
Pustule 22.74 19.67 9 10741 2016 79731622
Hiccups 22.46 19.67 15 10735 10016 79723622
Repetitive strain injury 22.35 19.67 5 10745 152 79733486
Gastric ulcer 22.07 19.67 25 10725 33880 79699758
Toxic epidermal necrolysis 21.12 19.67 28 10722 44553 79689085
Pharyngeal swelling 20.88 19.67 13 10737 7706 79725932
Acute haemorrhagic oedema of infancy 20.63 19.67 4 10746 59 79733579
Vulvovaginal inflammation 20.48 19.67 6 10744 540 79733098
Death 20.38 19.67 28 10722 566486 79167152

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01CF05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Beta-lactamase resistant penicillins
CHEBI has role CHEBI:36047 antibacterial drugs
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.76 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Androgen receptor Nuclear hormone receptor IC50 6.25 WOMBAT-PK
Matrix metalloproteinase-9 Enzyme IC50 4.19 WOMBAT-PK
Penicillin-binding protein 1A Enzyme WOMBAT-PK

External reference:

IDSource
N0000167002 NUI
D01249 KEGG_DRUG
C0016267 UMLSCUI
CHEBI:5098 CHEBI
CHEMBL222645 ChEMBL_ID
D005436 MESH_DESCRIPTOR_UI
DB00301 DRUGBANK_ID
10910 IUPHAR_LIGAND_ID
21319 PUBCHEM_CID
235750 RXNORM
003516 NDDF
003517 NDDF
387544009 SNOMEDCT_US
426208000 SNOMEDCT_US
96067005 SNOMEDCT_US
2308 INN_ID
43B2M34G2V UNII

Pharmaceutical products:

None